CarbaMic acid, [3-[trans-5-(6-Methoxy-1-naphthalenyl)-1,3-dioxan-2-yl]propyl]-, 2-aMino-2-oxoethyl ester

SSR411298 is an orally active, selective and reversible fatty acid amide hydrolase (FAAH) inhibitor. SSR411298 has the potential for post-traumatic stress disorder research[1]. SSR411298 (0.1, 1, 10, 100, 1000, 10000 nM) inhibits mouse brain FAAH in a concentration-dependent manner[1]. SSR411298 produces maximal inhibition of FAAH between 0.3 and 30 mg/kg in the ex-vivo experiment[1]. SSR411298 (0.3, 1, 3 mg/kg; p.o.; twice a day during 2 days; 60 minutes before pretest, immediately after, and 60 minutes before the second session of testing) produces robust antidepressant-like activity in the rat forced-swimming test and in the mouse chronic mild stress model, restoring notably the development of inadequate coping responses to chronic stress in male Wistar rats weighing 235-290 g[1]. SSR411298 (0.3, 1, 3, 10 mg/kg; po; single dose; two hours prior to sacrifice) produces a significant global increase of tissular AEA, PEA and OEA levels in the hippocampus, but not of 2-AG levels[1].

[1]. Guy Griebel, et al. The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents. Sci Rep. 2018 Feb 5;8(1):2416.